AstraZeneca is showcasing significant progress in hematology at the 67th American Society of Hematology Annual Meeting and Exposition from December 6 to 9, 2025, presenting the largest presence the company has ever had at ASH. The company will feature 65 abstracts covering eight approved and investigational medicines, including 15 oral presentations, reflecting the breadth and depth of its hematology portfolio and pipeline. Key presentations include updated three-year follow-up data from the Phase I first-in-human trial of surovatamig, a CD19xCD3 T-cell engager, in patients with relapsed or refractory follicular lymphoma; early Phase Ib/II results for AZD0120, an investigational BCMAxCD19 CAR T-cell therapy, in relapsed or refractory multiple myeloma; long-term Phase III ECHO trial results for CALQUENCE in combination with bendamustine and rituximab for first-line mantle cell lymphoma; and additional data from the ALXN1210-TMA-314 Phase III trial evaluating ULTOMIRIS in pediatric patients with HSCT-associated thrombotic microangiopathy.
Health Technology Insights: CMS Expands Reimbursement for Eko SENSORA AI Cardiac Platform
Anas Younes, Senior Vice President of Hematology R&D and Chief Medical Officer at AstraZeneca, stated that the company is making progress in developing a broad range of investigational therapies with the potential to transform care for patients with blood cancers. He emphasized that early efficacy and safety data from AZD0120 in multiple myeloma and surovatamig in B-cell malignancies demonstrate the potential of these novel therapies. Christophe Hotermans, Senior Vice President and Head of Global Medical Affairs at Alexion, added that the new data for ULTOMIRIS, including pediatric Phase III results, underscores the potential to improve outcomes and overall survival in rare hematologic conditions, reflecting AstraZeneca’s commitment to translating pioneering science into patient impact.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 2 December 2025
Other notable presentations include updated safety and efficacy data from the SYRUS Phase I/II trial of surovatamig in adolescents and adults with relapsed or refractory B-cell acute lymphoblastic leukemia, initial efficacy and safety findings for surovatamig in relapsed or refractory diffuse large B-cell lymphoma, follow-up results from investigator-initiated trials of AZD0120 in high-risk newly diagnosed multiple myeloma in China, preliminary TrAVeRse Phase II trial data for CALQUENCE combined with venetoclax and rituximab in treatment-naïve mantle cell lymphoma patients, and exploratory AMPLIFY Phase III analyses of CALQUENCE in first-line chronic lymphocytic leukemia. The ALPHA Phase III trial provided sub-analysis results for VOYDEYA as an add-on to ULTOMIRIS or SOLIRIS in adults with paroxysmal nocturnal hemoglobinuria, including older patients, and real-world evidence highlighted ULTOMIRIS outcomes in specific patient subgroups, including pregnant patients.
CALQUENCE is a Bruton tyrosine kinase inhibitor approved for adults with previously untreated mantle cell lymphoma in combination with bendamustine and rituximab when autologous hematopoietic stem cell transplantation is not an option, for previously treated mantle cell lymphoma, and for chronic lymphocytic leukemia or small lymphocytic lymphoma. AstraZeneca provides detailed safety information, noting that serious infections, including opportunistic infections, occurred in 32 percent of patients, with respiratory infections being the most common. Fatal and serious hemorrhagic events occurred in 4.4 percent of patients, and cytopenias of Grade 3 or 4 severity were reported in neutrophils, platelets, hemoglobin, and lymphocytes. Second primary malignancies occurred in 18 percent of patients, most commonly non-melanoma skin cancers. Cardiac arrhythmias, including atrial fibrillation and ventricular arrhythmias, were reported, with monitoring recommended. Hepatotoxicity and drug-induced liver injury have been observed, and liver function should be assessed at baseline and monitored during treatment. Patients should be carefully observed for infection, bleeding, cytopenias, arrhythmias, malignancies, and liver toxicity while on CALQUENCE, with dose adjustments or treatment interruptions as clinically indicated.
This year’s ASH presentations reinforce AstraZeneca’s commitment to advancing innovative therapies across the hematology landscape while providing clinicians with detailed data to support optimal patient management. By combining novel treatment approaches, long-term clinical evidence, and real-world insights, the company continues to pursue its mission of improving outcomes for patients with blood cancers and rare hematologic conditions.
AstraZeneca’s comprehensive portfolio at ASH 2025 highlights the integration of early-stage research, clinical development, and patient-focused real-world evidence to demonstrate both safety and efficacy across diverse hematology indications. With multiple therapies in development and ongoing trials, the company aims to deliver meaningful advances in patient care, inform future regulatory strategies, and provide physicians with evidence-based tools to improve survival, quality of life, and clinical outcomes in hematologic diseases.
Health Technology Insights: Proscia Achieves SOC 2 Type II Certification
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
